Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00547417 · ClinicalTrials.gov registry record · Phase 3
To Determine Effect and Safety of Tadalafil Taken by Men of Different Races and With Different Diseases When Needed for Erections
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,933
- Enrollment target
NCT00547417: Completed Phase 3 study, sponsored by Eli Lilly and Company.
NCT00547417 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 1,933 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (150% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00547417, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,933 participants
- Enrollment target
Study Summary
To compare men of different races and those with diabetes or depression to white men that do not have diabetes or depression but also suffer from the inability to get or keep an erection.
Interventions
- DRUG tadalafil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,933 participants |
| Start Date | 2003-07 |
| Est. Completion | 2004-03 |
| Phase | Phase 3 |
What the finished NCT00547417 record still lists
NCT00547417 is an interventional study that assigns participants to a tested intervention. Its 1,933 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (150% higher).
The record links to 0 conditions, and to 1 intervention - of which tadalafil is the first listed.
NCT00547417 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00547417 about?
NCT00547417 is a clinical study titled "To Determine Effect and Safety of Tadalafil Taken by Men of Different Races and With Different Diseases When Needed for Erections". To compare men of different races and those with diabetes or depression to white men that do not have diabetes or depression but also suffer from the inability to get or keep an erection.
What is the current status of trial NCT00547417?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,933 participants. The study started on 2003-07. Estimated completion is 2004-03.
What interventions are being tested in trial NCT00547417?
The interventions under investigation include: tadalafil (DRUG).
Who is sponsoring clinical trial NCT00547417?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00547417's enrollment target sits among peer trials
1,933 109th of 2000 higher than 1,892 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05233150 · 1,932 participants · NA
Child-Adult Relationship Enhancement in Primary Care (PriCARE) / Criando Niños Con CARIÑO (CARIÑO)
- NCT06058455 · 1,920 participants · NA
An Evaluation of an Online Sexual Assault Resistance Program (IDEA3)
- NCT05174169 · 1,912 participants · Phase 2
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
- NCT06799117 · 1,912 participants · NA
Adaptive Decision Support for Addiction Treatment Master
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia